Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol

Synapse

Volumn 34, Issue 3, 1999, Pages 192-207

  Yu, Jiang ^a   Källström, Lillemor ^a   Wiesel, Frits Axel ^a   Johnson, Allan E ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotics; Basal ganglia; D1 receptors; Extrapyramidal side effects; GAD65; GAD67

Indexed keywords

CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMATE DECARBOXYLASE; HALOPERIDOL; NEUROLEPTIC AGENT; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENTOPEDUNCULAR NUCLEUS; ENZYME REGULATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IN SITU HYBRIDIZATION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BINDING SITES; BINDING, COMPETITIVE; CLOZAPINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENTOPEDUNCULAR NUCLEUS; FEMALE; GLUTAMATE DECARBOXYLASE; HALOPERIDOL; IN SITU HYBRIDIZATION; MASTICATION; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RNA, MESSENGER; SALICYLAMIDES; TIME FACTORS;

EID: 0344980196     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(19991201)34:3<192::AID-SYN4>3.0.CO;2-L     Document Type: Article

References (125)

1. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
2. 1 receptors in brain demonstrated with digital subtraction autoradiography. J Neurosci 7:213-222.
3. Arbilla S, Langer S Z. 1981. Stereoselectivity of presynaptic autoreceptors modulating dopamine release. Eur J Pharmacol 76:345-351.
4. Arnt J. 1998. Pharmacological differentiation of classical and novel antipsychotics. Int Clin Psychopharmacol 13(Suppl 3):S7-S14.
5. Arnt J, Skarsfeldt T, Hyttel J. 1997. Differentiation of classical and novel antipsychotics using animal models. Int Clin Psychopharmacol 12(Suppl 1):S9-S17.
6. Baldessarini R J, Centorrino F, Flood J G, Volpicelli S A, Huston-Lyons D, Cohen BM. 1993. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124.
7. 2 receptors with specific cellular elements in the basal ganglia of the cat: the uneven topography of dopamine receptors in the striatum is determined by intrinsic striatal cells, not nigrostriatal axons. Neuroscience 27:851-863.
8. Bernard V, Normand E, Bloch B. 1992. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 12:3591-3600.
9. 125I]iodosulpiride. Neuroscience 20:117-155.
10. Brotchie J M, Mitchell I J, Sambrook M A, Crossman A R. 1991. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6:133-138.
11. Calabresi P, Centonze D, Pisani A, Sancesario G G, P, Marfia G A, Bernardi G. 1998. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 43:586-597.
12. Casey D E. 1995. Tardive dyskinesia: Pathophysiology. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 1497-1502.
13. Cepeda C, Buchwald N A, Levine M S. 1993. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576-9580.
14. Chen Q, Reiner A. 1996. Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res Dec 16;743:346-352.
15. Chen Q, Veenman C L, Reiner A. 1996. Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience 73:715-731.
16. Cheng Y F, Paalzow L K. 1992. Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 13:69-76.
17. Chesselet M-F, Soghomonian J-J, Salin P. 1995. Anatomical localization and regulation of somatostatin gene expression in the basal ganglia and its clinical implications. Ciba Found Symp 190:51-64.
18. Chesselet M-F, Weiss L, Wuenschell C, Tobin A J, Affolter H-U. 1987. Comparative distribution of mRNAs for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: in situ hybridization study in rodent brain. J Comp Neurol 262:125-140.
19. 1-receptors. Mol Brain Res 49:197-210.
20. Cotman C W, Kahle J S, Miller S E, Ulas J, Bridges R J. 1995. Excitatory amino acid neurotransmission. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 75-85.
21. Coward D M. 1992. General pharmacology of clozapine. Br J Psychiatry (Suppl) 17:5-11.
22. Dalack G W, Becks L, Meador-Woodruff J H. 1998. Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry 22:567-573.
23. Daly S A, Waddington J L. 1993. Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C. Psychopharmacology (Berl) 113:45-50.
24. Davé M. 1994. Clozapine-related tardive dyskinesia. Biol Psych 35:886-887.
25. 1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand. Neuroscience 26:83-100.
26. Delfs J M, Anegawa N J, Chesselet M-F. 1995a. Glutamate decarboxylase mRNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience 66:67-80.
27. Delfs J M, Ellison G D, Mercugliano M, Chesselet M-F. 1995b. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 133:175-188.
28. DeLong M R. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
29. Deveney A M, Waddington J L. 1995. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br J Pharmacol 116:2120-2126.
30. Deveney A M, Waddington J L. 1996. Evidence for dopamine 'D1-like' receptor subtypes in the behavioural effects of two new selective antagonists, LY 270411 and BW 737C. Eur J Pharmacol 317:175-181.
31. Diana M, Collu M, Mura A, Gessa G L. 1992. Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. Eur J Pharmacol 211:415-419.
32. Ekblom B, Eriksson K, Lindström L H. 1984. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 83:293-294.
33. Ellison G, See R, Levin E, Kinney J. 1987. Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology (Berl) 92:122-126.
34. Esclapez M, Tillakaratne N J K, Tobin A J, Houser C R. 1993. Comparative localization of mRNAs encoding two forms of glutamic acid decarboxylase with nonradioactive in situ hybridization methods. J Comp Neurol 331:339-362.
35. Fienberg A A, Hiroi N, Mermelstein P G, Song W, Snyder G L, Nishi A, Cheramy A, O'Callaghan J P, Miller D B, Cole D G, Corbett R, Haile C N, Cooper D C, Onn S P G, AA Ouimet, C C, White F J, Hyman S E, Surmeier D J, Girault J, Nestler E J, Greengard P. 1998. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281:838-842.
36. Figueredo-Cardenas G, Anderson K D, Chen Q, Veenman C L, Reiner A. 1994. Relative survival of striatal projection neurons and interneurons after interstriatal injection of quinolinic acid in rats. Exp Neurol 129:37-56.
37. 3H]-SCH 23390. Brain Res 408:205-209.
38. Fitzgerald L W, Deutch A Y, Gasic G, Heinemann S F, Nestler E J. 1995. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15:2453-2461.
39. 1 dopamine receptor binding in discrete brain areas of the male rat. Neurosci Lett 106:169-174.
40. Gao X M, Hashimoto T, Cooper T B, Tamminga C A. 1997. The dose-response characteristics of rat oral dyskinesias associated with chronic haloperidol and clozapine administration. J Neural Transm 104:97-104.
41. Gerfen C R, Wilson C J. 1996. The basal ganglia. In: Swanson LW, Björklund A, Hökfelt T, editors. Handbook of chemical anatomy: integrated systems of the CNS, Part III. Amsterdam: Elsevier. p 371-468.
42. Giardino L, Calza L, Piazza P V, and Amato G. 1991. Multiple neurochemical action of clozapine: a quantitative autoradiographic study of DA2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. J Neural Transm Gen Sect 83:189-203.
43. Graham W C, Robertson R G, Sambrook M A, Crossman A R. 1990. Injection of excitatory amino acid antagonists into the pallidal segment of the MPTP-treated monkey reverses motor symptoms of parkinsonism. Life Sci 47:91-97.
44. Gunne L M, Andersson U, Bondesson U, Johansson P. 1986. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 25:897-901.
45. Gunne L M, Barany S. 1976. Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology 50:237-240.
46. Gunne L M, Growden J, Glaeser B. 1982. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77:134-139.
47. Gunne L M, Häggström J E, Sjöquist B. 1984. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309:347-349.
48. 2 receptors. Psychopharmacology 103:6-18.
49. Hauber W. 1998. Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 56:507-540.
50. Herkenham M, Nauta W J H. 1977. Afferent connections of the habenular nuclei in the rat. A horseradish peroxidase study with a note on the fibres-of-passage problem. J Comp Neurol 173:123-146.
51. Herkenham M, Nauta W J H. 1979. Efferent connections of the habenular nuclei in the rat. J Comp Neurol 187:19-48.
52. Huang N, Ase A R, Hébert C, Van Gelder N M, Reader T A. 1997. Effects of chronic neuroleptic treatments on dopamine d1 and d2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 30:277-290.
53. Huhman K L, Hennessey A C, Albers H E. 1996. Rhythms of glutamic acid decarboxylase mRNA in the suprachiasmatic nucleus. J Biol Rhythms 11:311-316.
54. Ince E, Ciliax B J, Levey A I. 1997. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27:357-366.
55. Jaber M, Robinson S W, Missale C, Caron M G. 1996. Dopamine receptors and brain function. Neuropharmacology 35:1503-1519.
56. Jann M W, Grimsley S R, Gray E C, Chang W-H. 1993. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161-176.
57. 2 agonist on oral movements in rats. Eur J Pharmacol 134:83-88.
58. Johnson A E, Coirini H, Källström L, Gunne L, Wiesel F-A. 1995. Neuroleptics differentially modulate central dopamine D1-receptor binding. Neuroreport 6:933-936.
59. Johnson A E, Coirini H, Källström L, Wiesel F-A. 1994. Characterization of dopamine receptor binding sites in the subthalamic nucleus. Neuroreport 5:1836-1838.
60. Johnson A E, Liminga U, Lidén A, Lindefors N, Gunne L, Wiesel F-A. 1994. Chronic treatment with a classical neuroleptic alters excitatory amino acid transmission and GABA-ergic transmission in specific regions of the rat brain. Neuroscience 63:1003-1020.
61. Josselyn S A, Miller R, Beninger R J. 1997. Behavioral effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 21:531-558.
62. Kakigi T, Gao X-M, Tamminga C A. 1995. Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J Neural Transm [Gen Sect] 101:41-49.
63. Kane J, Honigfeld G, Singer J, Meltzer H Y. 1988. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
64. Kane J, Woener M, Pollick S, Safferman A, Lieberman J. 1993. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54:327-330.
65. Kaufman D L, Houser C R, Tobin A J. 1991. Two forms of the γ-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem 56:720-723.
66. Kawaguchi Y, Wilson C J, Emson P C. 1990. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 10:3421-3438.
67. 2-selective ligand 125I-NCQ 298. Neurosci-Lett 125:12-14.
68. Kurz M, Hummer M, Oberbauer H, Fleischacker W W. 1995. Extrapyramidal side effects of clozapine and haloperidol. Paychopharmacology 118:52-56.
69. 1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol 210:195-200.
70. 67) by dopamine receptors in the rat striatum. Mol Brain Res 34:65-74.
71. 65) gene expression is increased by dopamine receptor agonists in a subpopulation of rat striatal neurons. Mol Brain Res 48:333-345.
72. 2 receptor antagonists on oral activity in rats. Pharmacol Biochem Behav 34:43-48.
73. Levine M S, Altemus K L, Cepeda C, Cromwell H C, Crawford C, Ariano M A, Drago J, Sibley D R, Westphal H. 1996. Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. J Neurosci 16:5870-5882.
74. Liminga U, Johnson A E, Andrén P, Gunne L M. 1993. Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat. Pharmacol Biochem Behav 46:427-133.
75. 3H]SCH 23390 as ligands for the D-1 dopamine receptor. J Neurochem 51:391-397.
76. Martin D L, Martin S B, Wu S J, Espina N. 1991. Regulatory properties of brain glutamate decarboxylase (GAD): the apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain. J Neurosci 11:2725-2731.
77. Meltzer H Y. 1995. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 1277-1286.
78. Meltzer H Y, Chai B L, Thompson P A, Yamamoto B K. 1994. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J Pharmacol Exp Ther 268: 1452-1461.
79. Mercugliano M, SaLler C F, Salama A I, U'Prichard D C, Chesselet M-F. 1992. Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropsychopharmacology 6:179-187.
80. Mercugliano M, Soghomonian J J, Qin Y, Nguyen H Q, Feldblum S, Erlander M G, Tobin A J, Chesselet M F. 1992. Comparative distribution of messenger RNAs encoding glutamic acid decarboxylases (Mr 65,000 and Mr 67,000) in the basal ganglia of the rat. J Comp Neurol 318:245-254.
81. Mink J W. 1996. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 50:381-425.
82. Moriizumi T, Hattori T. 1992. Choline acetyltransferase-immunoreactive neurons in the rat entopeduncular nucleus. Neuroscience 46:721-728.
83. Mugnaini E, Oertel W F. 1985. An atlas of the distribution of GABAergic neurons and terminals in the rat CNS as revealed by GAD immunohistochemistry. In: Björkland A, Hökfelt T, editors. Handbook of chemical anatomy. Amsterdam: Elsevier. p 436-622.
84. Murray A M, Waddington J L. 1989. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur J Pharmacol 160:377-384.
85. Murray A M, Waddington J L. 1990. The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices. Eur J Pharmacol 186:79-86.
86. Neter J, Wasserman W. 1974. Applied linear statistical models. Homewood, IL: Richard D. Irwin.
87. Nowak J Z, Arbilla S, Galzin A M, Langer S Z. 1983. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol. J Pharmacol Exp Ther 226:558-564.
88. O'Dell S J, La Hoste G J, Widmark C B, Shapiro R M, Potkin S G, Marshall J F. 1990. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6:146-153.
89. Olianas M C, Maullu C, P O. 1997. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 122:401-408.
90. Olney J W. 1989. Excitotoxic lesions. In: Cotman CW, editor. Selective lesioning in the nervous system. Washington, DC: Society for Neuroscience. p 1-12.
91. Parent A, Hazrati L-N. 1995. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 20:91-127.
92. Pollack S, Lieberman J, Kleiner D, Szymanski S, Kane J, Borenstein M, Cooper T. 1993. High plasma clozapine levels in tardive dyskinesia. Psychopharmacol Bull 29:257-262.
93. 2 and N-methyl-D-aspartate binding sites in the nucleus of the solitary tract of the rat: possible relationship to investive behavior. Neuroscience 77:1077-1089.
94. Qin Y, Soghomonian J J, Chesselet M F. 1992. Effects of quinolinic acid on messenger RNAs encoding somatostatin and glutamic acid decarboxylases in the striatum of adult rats. Exp Neurol 115:200-211.
95. Rajakumar N, Elisevich K, Flumerfelt B A. 1993. Compartmental origin of the striato-entopeduncular projection in the rat. J Comp Neurol 331:286-296.
96. Rajakumar N, Laurier L, Niznik H B, Stoessl A J. 1997. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat. Synapse 26:199-208
97. Rasband W S, Bright D S. 1995. NIH image: a public domain image processing program for the Macintosh. Microbeam Anal Soc J 4:137-149.
98. Reader T A, Ase A R, Huang N, Hebert C, van Gelder N M. 1998. Neuroleptics and dopamine transporters. Neurochem Res 23:73-80.
99. Roberts R C, Gaither L A, Gao X-M, Kashyap S M, Tamminga C A. 1995. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse 20:234-243.
100. Rosengarten H, Schweitzer J W, Friedhoff A J. 1983. Induction of oral dyskinesia in naive rats by D1-stimulation. Life Sci 33:2479-2484.
101. Rupniak N M, Hall M D, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden C D. 1985. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol 34:2755-2763.
102. Sahakian B J, Robbins T W, Iversen S D. 1976. Alpha-flupenthixol-induced hyperactivity by chronic dosing in rats. Eur J Pharmacol 37:169-178.
103. See R E, Levin E D, Ellison G D. 1988. Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration. Psychopharmacology (Berl) 94:421-427.
104. See R W, Chapman M A. 1994. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur J Pharmacol 263:269-276.
105. Seeman P. 1995. Dopamine receptors: clinical correlates. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 295-302.
106. Seeman P, Grigoriadis D. 1987. Dopamine receptors in brain and periphery. Neurochem Int 10:1-25.
107. Soghomonian J-J, Chesselet M F. 1992. Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat. Synapse 11:124-133.
108. Stoessl A J, Rajakumar N. 1996. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. Synapse 24:256-261.
109. Surmeier D J, Song W-J, Yan Z. 1996. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16:6579-6591.
110. Swanson L W. 1992. Brain maps: structure of the rat brain. Amsterdam: Elsevier.
111. Tallaksen-Greene S J, Kaatz K W, Romano C, Albin R L. 1998. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res 780:210-217.
112. Tamminga C A, Thaker G K, Moran M, Kakigi T, Gao X M. 1994. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55(Suppl B):102-106.
113. Tarazi F I, Florijn W J, Creese I. 1997. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 78:985-996.
114. Ulas J, Cotman C W. 1996. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. Neuroreport 7:1789-1793.
115. van der Kooy D, Carter D A. 1981. The organization of the efferent projections and striatal afferents of the entopeduncular nucleus and adjacent areas in the rat. Brain Res 211:15-36.
116. Verghese C, DeLeon J, Nair C, Simpson G M. 1996. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 39:135-138.
117. Vincent S R, Brown J C. 1986. Somatostatin immunoreactivity in the entopeduncular projection to the lateral habenula in the rat. Neurosci Lett 68:160-164.
118. Waddington J L. 1990. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431-447.
119. Waddington J L, Cross A J, Gamble S J, Bourne S J. 1983. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530-532.
120. Yoshida M, Rabin A, Anderson M. 1972. Monosynaptic inhibition of pallidal neurons by axon collaterals of caudate nigral fibers. Exp Brain Res 15:337-347.
121. Young III W S. 1992. In situ hybridization with oligodeoxyribonucleotide probes. In: Wilkinson DG, editor. In situ hybridization: a practical approach. Oxford: IRL Press. p 33-44.
122. 1-receptor antagonist, SCH-23390. Synapse 30:38-48.
123. 67 mRNA in the entopeduncular nucleus of the rat. Neuroscience 78:87-97.
124. Zadow B, Schmidt W J. 1994. Lesions of the entopeduncular and the subthalamic nucleus reduce dopamine receptor antagonist-induced catelepsy in the rat. Behav Brain Res 62:71-79.
125. Zetterstrom T, Ungerstedt U. 1984. Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. Eur J Pharmacol 97:29-36.